凯因科技：间接持有先为达3.44%股权

Core Viewpoint - Company currently holds an indirect stake of 3.44% in Xianweida, indicating a strategic investment in the biopharmaceutical sector [1] Group 1 - Company has signed an agreement with Xianweida regarding the development of its GLP-1 drug, establishing terms for future revenue generated from this product [1] - Company advises stakeholders to refer to Xianweida's public disclosures for updates on the drug's progress [1]